NASDAQ:AGIO Agios Pharmaceuticals (AGIO) Stock Price, News & Analysis → Thousands of investors use this no cost solution | Do you? (From Insider Financial) (Ad) Free AGIO Stock Alerts $31.81 +1.60 (+5.30%) (As of 05:26 PM ET) Add Compare Share Share Today's Range$30.40▼$33.0250-Day Range$25.15▼$34.8152-Week Range$19.80▼$35.50Volume1.23 million shsAverage Volume811,410 shsMarket Capitalization$1.79 billionP/E RatioN/ADividend YieldN/APrice Target$33.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Agios Pharmaceuticals alerts: Email Address Agios Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside5.3% Upside$33.50 Price TargetShort InterestBearish12.06% of Float Sold ShortDividend StrengthN/ASustainability-0.81Upright™ Environmental ScoreNews Sentiment0.18Based on 2 Articles This WeekInsider TradingSelling Shares$950,297 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($5.11) to ($5.86) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.32 out of 5 starsMedical Sector729th out of 910 stocksPharmaceutical Preparations Industry338th out of 426 stocks 1.3 Analyst's Opinion Consensus RatingAgios Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageAgios Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted12.06% of the float of Agios Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAgios Pharmaceuticals has a short interest ratio ("days to cover") of 8.3.Change versus previous monthShort interest in Agios Pharmaceuticals has recently decreased by 3.65%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAgios Pharmaceuticals does not currently pay a dividend.Dividend GrowthAgios Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAgios Pharmaceuticals has received a 75.34% net impact score from Upright. Agios Pharmaceuticals seems to create the most significant positive value in categories "Jobs", "Physical diseases", and "Creating knowledge". The positive contribution in the "Physical diseases" impact category is mostly driven by its "Preclinical research services for physical health", "Clinical research services for cancer", and "Clinical research services for metabolic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Agios Pharmaceuticals is -0.81. Previous Next 1.2 News and Social Media Coverage News SentimentAgios Pharmaceuticals has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Agios Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for AGIO on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Agios Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Agios Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $950,297.00 in company stock.Percentage Held by InsidersOnly 4.24% of the stock of Agios Pharmaceuticals is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Agios Pharmaceuticals are expected to decrease in the coming year, from ($5.11) to ($5.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Agios Pharmaceuticals is -5.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Agios Pharmaceuticals is -5.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAgios Pharmaceuticals has a P/B Ratio of 2.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressThe system that called 2023’s top 7 stocks is at it again…Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here! About Agios Pharmaceuticals Stock (NASDAQ:AGIO)Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Read More AGIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AGIO Stock News HeadlinesApril 12, 2024 | insidertrades.comJacqualyn A. Fouse Sells 7,791 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) StockApril 18, 2024 | globenewswire.comAgios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024April 23, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.April 10, 2024 | finance.yahoo.comDirector Jacqualyn Fouse Sells Shares of Agios Pharmaceuticals Inc (AGIO)April 9, 2024 | finance.yahoo.comAgios Publishes 2024 Environmental, Social and Governance (ESG) ReportApril 2, 2024 | finanznachrichten.deOncoinvent AS: Oncoinvent Announces Changes to its Board of Directors and Formation of Scientific and Clinical Advisory BoardMarch 16, 2024 | finance.yahoo.comAGIO Apr 2024 40.000 callMarch 16, 2024 | finance.yahoo.comAGIO Apr 2024 25.000 putApril 23, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.March 8, 2024 | uk.finance.yahoo.comAsset Purchase Deals in Pharmaceuticals and Biotechnology 2016-2024: Trends, Deal Structure, Leading Deals by Value, Most Active Dealmakers, and MoreMarch 5, 2024 | globenewswire.comAgios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024February 28, 2024 | morningstar.comAgios Pharmaceuticals Inc AGIOFebruary 24, 2024 | msn.comSCIEX’s Jose Castro-Perez Reveals How They're Setting New Standards in Mass SpectrometryFebruary 24, 2024 | msn.comAgios Pharmaceuticals (AGIO) Price Target Increased by 7.00% to 43.66February 23, 2024 | finance.yahoo.comAgios Pharmaceuticals Stock Earns RS Rating Upgrade; Hits Key BenchmarkFebruary 22, 2024 | finance.yahoo.comAgios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024February 22, 2024 | globenewswire.comAgios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024February 20, 2024 | finance.yahoo.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q4 2023 Earnings Call TranscriptFebruary 18, 2024 | finance.yahoo.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Reported And Analysts Have Been Cutting Their EstimatesFebruary 17, 2024 | finance.yahoo.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Slashed This Year's EstimatesFebruary 16, 2024 | finance.yahoo.comAgios (AGIO) Q4 Earnings & Revenues Fall Short of EstimatesFebruary 16, 2024 | markets.businessinsider.comBuy Rating for Agios Pharma Amid Expanding Drug Pipeline and Strong Commercial ProspectsFebruary 16, 2024 | markets.businessinsider.comBuy Rating Justified by Agios Pharma’s Promising Trials and Future ProspectsFebruary 16, 2024 | finance.yahoo.comQ4 2023 Agios Pharmaceuticals Inc Earnings CallFebruary 15, 2024 | finance.yahoo.comAgios Pharmaceuticals (AGIO) Reports Q4 Loss, Misses Revenue EstimatesFebruary 15, 2024 | finance.yahoo.comAgios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsFebruary 15, 2024 | finance.yahoo.comAgios Pharmaceuticals Inc (AGIO) Reports Mixed Fourth Quarter and Full Year 2023 Financial ResultsSee More Headlines Receive AGIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/15/2024Today4/23/2024Next Earnings (Confirmed)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AGIO CUSIPN/A CIK1439222 Webwww.agios.com Phone(617) 649-8600FaxN/AEmployees383Year FoundedN/APrice Target and Rating Average Stock Price Target$33.50 High Stock Price Target$42.00 Low Stock Price Target$28.00 Potential Upside/Downside+10.9%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($6.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-352,090,000.00 Net Margins-1,312.64% Pretax Margin-1,312.64% Return on Equity-38.08% Return on Assets-33.69% Debt Debt-to-Equity RatioN/A Current Ratio12.27 Quick Ratio11.99 Sales & Book Value Annual Sales$26.82 million Price / Sales63.29 Cash FlowN/A Price / Cash FlowN/A Book Value$14.51 per share Price / Book2.08Miscellaneous Outstanding Shares56,190,000Free Float53,812,000Market Cap$1.70 billion OptionableOptionable Beta0.83 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Brian M. Goff M.B.A. (Age 55)CEO & Director Comp: $1.23MMs. Cecilia Jones (Age 49)Chief Financial Officer Comp: $403.36kMr. James William Burns (Age 46)Corporate Secretary & Chief Legal Officer Comp: $660.33kDr. Sarah Gheuens M.D. (Age 43)Ph.D., Chief Medical Officer and Head of Research & Development Comp: $769.2kDr. Lewis Clayton Cantley Ph.D. (Age 75)Co-Founder & Member of Scientific Advisory Board Comp: $50kDr. Tak Wah Mak D.Sc. (Age 78)FRSC, Ph.D., Co-Founder & Member of Scientific Advisory Board Dr. Craig B. Thompson M.D. (Age 71)Co-Founder & Chairman of Scientific Advisory Board Dr. Shin-San Su Ph.D. (Age 68)Co-Founder & Member of Scientific Advisory Board Mr. T. J. Washburn Jr. (Age 43)Principal Accounting Officer Dr. Clive Patience Ph.D. (Age 60)Chief Technical Operations Officer More ExecutivesKey CompetitorsSupernus PharmaceuticalsNASDAQ:SUPNAvadel PharmaceuticalsNASDAQ:AVDLTaro Pharmaceutical IndustriesNYSE:TAROAmneal PharmaceuticalsNASDAQ:AMRXArdelyxNASDAQ:ARDXView All CompetitorsInsiders & InstitutionsJacqualyn A FouseSold 7,791 sharesTotal: $214,642.05 ($27.55/share)Vanguard Group Inc.Bought 59,851 shares on 3/11/2024Ownership: 9.837%Fisher Asset Management LLCSold 105,898 shares on 3/5/2024Ownership: 1.266%Brian GoffSold 4,156 sharesTotal: $135,360.92 ($32.57/share)James William BurnsSold 2,642 sharesTotal: $86,049.94 ($32.57/share)View All Insider TransactionsView All Institutional Transactions AGIO Stock Analysis - Frequently Asked Questions Should I buy or sell Agios Pharmaceuticals stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AGIO shares. View AGIO analyst ratings or view top-rated stocks. What is Agios Pharmaceuticals' stock price target for 2024? 4 Wall Street research analysts have issued 1-year price targets for Agios Pharmaceuticals' stock. Their AGIO share price targets range from $28.00 to $42.00. On average, they anticipate the company's share price to reach $33.50 in the next twelve months. This suggests a possible upside of 5.3% from the stock's current price. View analysts price targets for AGIO or view top-rated stocks among Wall Street analysts. How have AGIO shares performed in 2024? Agios Pharmaceuticals' stock was trading at $22.27 at the beginning of 2024. Since then, AGIO stock has increased by 42.8% and is now trading at $31.81. View the best growth stocks for 2024 here. When is Agios Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our AGIO earnings forecast. How can I listen to Agios Pharmaceuticals' earnings call? Agios Pharmaceuticals will be holding an earnings conference call on Thursday, May 2nd at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link. How were Agios Pharmaceuticals' earnings last quarter? Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) released its quarterly earnings results on Thursday, February, 15th. The biopharmaceutical company reported ($1.72) earnings per share for the quarter, missing the consensus estimate of ($1.64) by $0.08. The biopharmaceutical company earned $7.10 million during the quarter, compared to the consensus estimate of $7.80 million. Agios Pharmaceuticals had a negative net margin of 1,312.64% and a negative trailing twelve-month return on equity of 38.08%. The company's revenue for the quarter was up 65.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.67 earnings per share. What ETFs hold Agios Pharmaceuticals' stock? ETFs with the largest weight of Agios Pharmaceuticals (NASDAQ:AGIO) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), WisdomTree BioRevolution Fund (WDNA), Tema Oncology ETF (CANC) and ALPS Medical Breakthroughs ETF (SBIO).Amplify Etho Climate Leadership U.S. ETF (ETHO). What is Jackie Fouse's approval rating as Agios Pharmaceuticals' CEO? 11 employees have rated Agios Pharmaceuticals Chief Executive Officer Jackie Fouse on Glassdoor.com. Jackie Fouse has an approval rating of 100% among the company's employees. This puts Jackie Fouse in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Agios Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), bluebird bio (BLUE), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), Tesla (TSLA) and Netflix (NFLX). How do I buy shares of Agios Pharmaceuticals? Shares of AGIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AGIO) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingHow to camouflage a factory of 53,000 workersStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersExposed: How Big Banks Plan to Chain Your Wealth with Digital DollarsGoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agios Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
